Ann: CEO presentation to Broker Meets Biotech - Perth, page-14

ajostu,

As you know there are know givens in biotech land. But every bit of data we have suggests that the trail data is very good indeed.

I think normally we would see an sp of 10c at this stage, but ftt still bears the scars of tis - even though it's a different team and a different approach. The new money won't care about the past.

Great days ahead imho, with just a small chance of failure.

There are more indications too, so success here has other upsides.

cheers